Jill Johnson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jill Johnson has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anand Shewale
Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
1 shared publication Benjamin Teeter
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas
1 shared publication- Bradley C. Martin
Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
1 shared publication Carrie McAdam-Marx
University of Arkansas for Medical Sciences College of Pharmacy, Little Rock
1 shared publicationCheng Peng
University of Arkansas for Medical Sciences (UAMS), Little Rock, Arkansas
1 shared publication- Chenghui Li
Division of Pharmaceutical Evaluation and Policy, College of Pharmacy, University of Arkansas for Medical Sciences, 4301 W. Markham St, Little Rock, AR 72205, USA
1 shared publication
Latest Publications
- Open Access
- 22 September 2025
- Published by Annals of Family Medicine in The Annals of Family Medicine
- Vol. 23 (5) , 407-411
Measurement of Practice-Level Antibiotic Utilization in a Medicaid Patient-Centered Medical Home Program
PURPOSE Outpatient antibiotic stewardship needs efficient strategies to remedy pervasive overuse. A claims-based measure of practice-specific antibiotic utilization in a Medicaid patient-centered medical home (PCMH) program was developed, implemented, and measured. METHODS This observational study analyzed outpatient antibiotic paid claims attributed to PCMH panels during 2019, 2020, and 2021. Practices received quarterly antibiotic prescribing rate report cards, as paid claims per 1,000 patients per year which included specific performance in comparison to other PCMHs. We identified high-, middle-, and low-utilization sites at baseline and then tracked prescribing during the observation period. Arkansas Medicaid data were compared with all-payer state and national data measured by the IQVIA and published annually by the Centers for Disease Control and Prevention. RESULTS In 2019, 176 of 216 PCMH sites met inclusion criteria. Cohort prescription rates were 1,089 in 2019, 785 in 2020, and 853 in 2021. Arkansas IQVIA all-payer rates for years 2019, 2020, and 2021 were 1,028, 844, and 927, while national IQVIA rates were lower at 765, 613, and 636, respectively. The Arkansas PCMH practice prescription rates in 2019 ranged from 720 to 1,491. By 2021, the range was 564 to 1,140. PCMH data showed reduced antibiotic prescribing in 2021 vs 2019 compared with national and state-specific IQVIA all-payer data analysis. CONCLUSIONS Analysis of antibiotic prescriptions per 1,000 patients at the practice level is feasible. Regular report cards to PCMHs were associated with reduced prescribing rates in 2021 relative to IQVIA national and state data.
- 22 September 2025
- Published by Annals of Family Medicine in The Annals of Family Medicine
- Vol. 23 (5) , 407-411
Open AccessMeasurement of Practice-Level Antibiotic Utilization in a Medicaid Patient-Centered Medical Home Program
PURPOSE Outpatient antibiotic stewardship needs efficient strategies to remedy pervasive overuse. A claims-based measure of practice-specific antibiotic utilization in a Medicaid patient-centered medical home (PCMH) program was developed, implemented, and measured. METHODS This observational study analyzed outpatient antibiotic paid claims attributed to PCMH panels during 2019, 2020, and 2021. Practices received quarterly antibiotic prescribing rate report cards, as paid claims per 1,000 patients per year which included specific performance in comparison to other PCMHs. We identified high-, middle-, and low-utilization sites at baseline and then tracked prescribing during the observation period. Arkansas Medicaid data were compared with all-payer state and national data measured by the IQVIA and published annually by the Centers for Disease Control and Prevention. RESULTS In 2019, 176 of 216 PCMH sites met inclusion criteria. Cohort prescription rates were 1,089 in 2019, 785 in 2020, and 853 in 2021. Arkansas IQVIA all-payer rates for years 2019, 2020, and 2021 were 1,028, 844, and 927, while national IQVIA rates were lower at 765, 613, and 636, respectively. The Arkansas PCMH practice prescription rates in 2019 ranged from 720 to 1,491. By 2021, the range was 564 to 1,140. PCMH data showed reduced antibiotic prescribing in 2021 vs 2019 compared with national and state-specific IQVIA all-payer data analysis. CONCLUSIONS Analysis of antibiotic prescriptions per 1,000 patients at the practice level is feasible. Regular report cards to PCMHs were associated with reduced prescribing rates in 2021 relative to IQVIA national and state data.
- 1 June 2019
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 25 (6) , 646-651
Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have repeatedly shown no reduction in the clinical outcomes of cardiovascular death, myocardial infarction, stroke, or all-cause mortality. Bec...
- 1 June 2019
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care & Specialty Pharmacy
- Vol. 25 (6) , 646-651
Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan
BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors have repeatedly shown no reduction in the clinical outcomes of cardiovascular death, myocardial infarction, stroke, or all-cause mortality. Bec...
- Open Access
- 1 January 2019
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 5 (1) , e82-e85
Severe, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
- 1 January 2019
- Published by Elsevier in AACE Clinical Case Reports
- Vol. 5 (1) , e82-e85
Open AccessSevere, Prolonged, Denosumab-Induced Hypocalcemia With Recovery After 111 Days Of High-Dose Calcium Supplementation
- Open Access
- 5 March 2015
- Published by MDPI AG in Healthcare
- Vol. 3 (1) , 130-145
Variation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation
Published atrial fibrillation (AF) guidelines and decision tools offer oral anticoagulant (OAC) recommendations; however, they consider stroke and bleeding risk differently. The aims of our study are: (i) to compare the variation in OAC recommendations by the 2012 American College of Chest Physicians guidelines, the 2012 European Society of Cardiology (ESC) guidelines, the 2014 American Heart Association (AHA) guidelines and two published decision tools by Casciano and LaHaye; (ii) to compare the concordance with actual OAC use in the overall study population and the population stratified by stroke/bleed risk. A cross-sectional study using the 2001–2013 Lifelink claims data was used to contrast the treatment recommendations by these decision aids. CHA2DS2-VASc and HAS-BLED algorithms were used to stratify 15,129 AF patients into nine stroke/bleed risk groups to study the variation in treatment recommendations and concordance with actual OAC use/non-use. The AHA guidelines which were set to recommend OAC when CHA2DS2-VASc = 1 recommended OAC most often (86.30%) and the LaHaye tool recommended OAC the least often (14.91%). OAC treatment recommendations varied considerably when stroke risk was moderate or high (CHA2DS2-VASc > 0). Actual OAC use/non-use was highly discordant (>40%) with all of the guidelines or decision tools reflecting substantial opportunities to improve AF OAC decisions.
- 5 March 2015
- Published by MDPI AG in Healthcare
- Vol. 3 (1) , 130-145
Open AccessVariation in Anticoagulant Recommendations by the Guidelines and Decision Tools among Patients with Atrial Fibrillation
Published atrial fibrillation (AF) guidelines and decision tools offer oral anticoagulant (OAC) recommendations; however, they consider stroke and bleeding risk differently. The aims of our study are: (i) to compare the variation in OAC recommendations by the 2012 American College of Chest Physicians guidelines, the 2012 European Society of Cardiology (ESC) guidelines, the 2014 American Heart Association (AHA) guidelines and two published decision tools by Casciano and LaHaye; (ii) to compare the concordance with actual OAC use in the overall study population and the population stratified by stroke/bleed risk. A cross-sectional study using the 2001–2013 Lifelink claims data was used to contrast the treatment recommendations by these decision aids. CHA2DS2-VASc and HAS-BLED algorithms were used to stratify 15,129 AF patients into nine stroke/bleed risk groups to study the variation in treatment recommendations and concordance with actual OAC use/non-use. The AHA guidelines which were set to recommend OAC when CHA2DS2-VASc = 1 recommended OAC most often (86.30%) and the LaHaye tool recommended OAC the least often (14.91%). OAC treatment recommendations varied considerably when stroke risk was moderate or high (CHA2DS2-VASc > 0). Actual OAC use/non-use was highly discordant (>40%) with all of the guidelines or decision tools reflecting substantial opportunities to improve AF OAC decisions.
- Open Access
- 1 April 2011
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 17 (3) , 200-212
Five-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan
The Arkansas State Employee Benefits Division (EBD) is a self-insured program comprising public school and other state employees, their spouses, and dependents. Previous research published in JMCP (2006) showed drug cost savings of $2.20 per member per month (PMPM; 37.6%) or annualized savings of $3.4 million associated with a benefit design change and coverage of the proton pump inhibitor (PPI) omeprazole over-the-counter (OTC) beginning in March 2004. On May 1, 2005, brand esomeprazole was excluded from coverage, with current users grandfathered for 4 months until September 2005. Reference pricing for PPIs, including esomeprazole but excluding generic omeprazole, was implemented on September 1, 2005, and the beneficiary cost share for all PPIs except generic omeprazole was determined from comparison of the PPI actual price to the $0.90 omeprazole OTC reference price per unit. To examine PPI utilization and drug costs before and after (a) excluding esomeprazole from coverage (with grandfathering current users) and (b) implementing a therapeutic maximum allowable cost (TMAC), or reference-pricing benefit design, for the PPI class in a large state employee health plan with fairly stable enrollment of approximately 127,500 members in 2005 through 2008 and approximately 128,000 members in 2009 Q1. The pharmacy claims database for the EBD was used to examine utilization and cost data for PPIs in a longitudinal analysis for the 61-month period from March 1, 2004, through March 31, 2009. Pharmacy claims data were compared for the period 14 months prior to esomeprazole exclusion (preperiod), 4 months during the esomeprazole exclusion (postperiod 1), and the ensuing 43 months of PPI reference pricing (postperiod 2). PPI cost and utilization data for the intervention group of approximately 127,500 beneficiaries were compared with a group of 122 self-insured employers with a total of nearly 1 million beneficiaries whose pharmacy benefits did not include reference pricing for PPIs. Despite 79% of existing esomeprazole users being grandfathered during the 4-month esomeprazole-exclusion period (postperiod 1), the share of omeprazole OTC claims increased from 35.2% to 42.5% (+ 7.3 percentage points) of all PPI claims, and esomeprazole claims decreased from 16.7% to 12.0% (-4.7 percentage points), with little change in the use of other PPIs. The average allowed charge (price) per day of PPI drug therapy decreased in postperiod 1 by 8.9% from $2.81 to $2.56, while utilization increased by 2.2% from 1.83 days PMPM to 1.87 days PMPM; the net plan cost PMPM decreased by $0.40 PMPM from $3.78 to $3.38 (-10.6%), representing a reduction in spending of $35,664 per month while the average member copayment per claim was essentially unchanged. In the 43 months of reference pricing in postperiod 2, PPI utilization was essentially unchanged at 1.82 days PMPM compared with the preperiod (1.83 days PMPM) and 2.7% lower than the esomeprazole-exclusion period (1.87 days PMPM); however, price (charge per day) decreased by 38.4% during refer- RESEARCH ence pricing to $1.73 from $2.81 in the preperiod and by 32.4% compared with $2.56 in the esomeprazole-exclusion period, despite an increase in the average pharmacy dispensing fee to $5.21 per PPI claim. Net plan cost decreased by $1.87 PMPM (49.5%) to $1.91 PMPM during reference pricing compared with the preperiod ($3.78 PMPM) and by $1.47 PMPM (43.5%) compared with the esomeprazole-exclusion period 1 ($3.38 PMPM). Beneficiary costs (copayment per claim) for PPIs decreased to $1.24 PMPM ($23.27 per claim) compared with the preperiod ($1.37 PMPM, $24.95 per claim) and compared with the esomeprazole-exclusion period ($1.40 PMPM, $25.06 per claim). The reductions in net plan costs represented lower plan spending for the 43 months of reference pricing (postperiod 2) of approximately $9.4 million or an average of approximately $219,500 per month compared with the preperiod or $7.9 million (approximately $183,900 per month) compared with the esomeprazole-exclusion period. Compared with a group of self-insured health plans without pharmacy benefit reference pricing of PPIs, the cost savings over the 43-month period from September 1, 2005, through March 31, 2009, were approximately $7.2 million or $1.31 PMPM. For this state employee health plan, the policy change that excluded esomeprazole from coverage but grandfathered current users was associated with a relatively small reduction in PMPM spending on PPIs compared with the subsequent policy change that applied reference pricing to the PPI class based on the price (drug cost plus dispensing fee) for omeprazole OTC. Over 43 months of reference pricing, net plan costs fell dramatically by 49.5% PMPM compared with the preperiod or decreased by 43.5% compared with the esomeprazole-exclusion period. While utilization was essentially unchanged compared with the 18 months before reference pricing, the average pharmacy dispensing fee per PPI claim increased, and beneficiary costs PMPM decreased.
- 1 April 2011
- Published by Academy of Managed Care Pharmacy in Journal of Managed Care Pharmacy
- Vol. 17 (3) , 200-212
Open AccessFive-Year Examination of Utilization and Drug Cost Outcomes Associated with Benefit Design Changes Including Reference Pricing for Proton Pump Inhibitors in a State Employee Health Plan
The Arkansas State Employee Benefits Division (EBD) is a self-insured program comprising public school and other state employees, their spouses, and dependents. Previous research published in JMCP (2006) showed drug cost savings of $2.20 per member per month (PMPM; 37.6%) or annualized savings of $3.4 million associated with a benefit design change and coverage of the proton pump inhibitor (PPI) omeprazole over-the-counter (OTC) beginning in March 2004. On May 1, 2005, brand esomeprazole was excluded from coverage, with current users grandfathered for 4 months until September 2005. Reference pricing for PPIs, including esomeprazole but excluding generic omeprazole, was implemented on September 1, 2005, and the beneficiary cost share for all PPIs except generic omeprazole was determined from comparison of the PPI actual price to the $0.90 omeprazole OTC reference price per unit. To examine PPI utilization and drug costs before and after (a) excluding esomeprazole from coverage (with grandfathering current users) and (b) implementing a therapeutic maximum allowable cost (TMAC), or reference-pricing benefit design, for the PPI class in a large state employee health plan with fairly stable enrollment of approximately 127,500 members in 2005 through 2008 and approximately 128,000 members in 2009 Q1. The pharmacy claims database for the EBD was used to examine utilization and cost data for PPIs in a longitudinal analysis for the 61-month period from March 1, 2004, through March 31, 2009. Pharmacy claims data were compared for the period 14 months prior to esomeprazole exclusion (preperiod), 4 months during the esomeprazole exclusion (postperiod 1), and the ensuing 43 months of PPI reference pricing (postperiod 2). PPI cost and utilization data for the intervention group of approximately 127,500 beneficiaries were compared with a group of 122 self-insured employers with a total of nearly 1 million beneficiaries whose pharmacy benefits did not include reference pricing for PPIs. Despite 79% of existing esomeprazole users being grandfathered during the 4-month esomeprazole-exclusion period (postperiod 1), the share of omeprazole OTC claims increased from 35.2% to 42.5% (+ 7.3 percentage points) of all PPI claims, and esomeprazole claims decreased from 16.7% to 12.0% (-4.7 percentage points), with little change in the use of other PPIs. The average allowed charge (price) per day of PPI drug therapy decreased in postperiod 1 by 8.9% from $2.81 to $2.56, while utilization increased by 2.2% from 1.83 days PMPM to 1.87 days PMPM; the net plan cost PMPM decreased by $0.40 PMPM from $3.78 to $3.38 (-10.6%), representing a reduction in spending of $35,664 per month while the average member copayment per claim was essentially unchanged. In the 43 months of reference pricing in postperiod 2, PPI utilization was essentially unchanged at 1.82 days PMPM compared with the preperiod (1.83 days PMPM) and 2.7% lower than the esomeprazole-exclusion period (1.87 days PMPM); however, price (charge per day) decreased by 38.4% during refer- RESEARCH ence pricing to $1.73 from $2.81 in the preperiod and by 32.4% compared with $2.56 in the esomeprazole-exclusion period, despite an increase in the average pharmacy dispensing fee to $5.21 per PPI claim. Net plan cost decreased by $1.87 PMPM (49.5%) to $1.91 PMPM during reference pricing compared with the preperiod ($3.78 PMPM) and by $1.47 PMPM (43.5%) compared with the esomeprazole-exclusion period 1 ($3.38 PMPM). Beneficiary costs (copayment per claim) for PPIs decreased to $1.24 PMPM ($23.27 per claim) compared with the preperiod ($1.37 PMPM, $24.95 per claim) and compared with the esomeprazole-exclusion period ($1.40 PMPM, $25.06 per claim). The reductions in net plan costs represented lower plan spending for the 43 months of reference pricing (postperiod 2) of approximately $9.4 million or an average of approximately $219,500 per month compared with the preperiod or $7.9 million (approximately $183,900 per month) compared with the esomeprazole-exclusion period. Compared with a group of self-insured health plans without pharmacy benefit reference pricing of PPIs, the cost savings over the 43-month period from September 1, 2005, through March 31, 2009, were approximately $7.2 million or $1.31 PMPM. For this state employee health plan, the policy change that excluded esomeprazole from coverage but grandfathered current users was associated with a relatively small reduction in PMPM spending on PPIs compared with the subsequent policy change that applied reference pricing to the PPI class based on the price (drug cost plus dispensing fee) for omeprazole OTC. Over 43 months of reference pricing, net plan costs fell dramatically by 49.5% PMPM compared with the preperiod or decreased by 43.5% compared with the esomeprazole-exclusion period. While utilization was essentially unchanged compared with the 18 months before reference pricing, the average pharmacy dispensing fee per PPI claim increased, and beneficiary costs PMPM decreased.
- 17 August 1982
- Published by The Haworth Press in Journal of Divorce
- Vol. 5 (4) , 41-53
LEARNING THE SINGLE-PARENT ROLE
Data from previous research and from new interviews with 30 divorced custodial parents are explored to develop a model of how traditional marital roles influence the adjustment to single parenthood. The results reemphasize the applicability of Hill's (1958) ABCX model of adapting to family crisis. Interpretations of needed changes are as important as instrumental competence. The adjustment model is developed for application in educational and counseling settings dealing with single parents.
- 17 August 1982
- Published by The Haworth Press in Journal of Divorce
- Vol. 5 (4) , 41-53
LEARNING THE SINGLE-PARENT ROLE
Data from previous research and from new interviews with 30 divorced custodial parents are explored to develop a model of how traditional marital roles influence the adjustment to single parenthood. The results reemphasize the applicability of Hill's (1958) ABCX model of adapting to family crisis. Interpretations of needed changes are as important as instrumental competence. The adjustment model is developed for application in educational and counseling settings dealing with single parents.